OmegaGenesis, Inc. is a bio-technology company based in California and Minnesota. The Company was founded in 2008 to bring Mayo Clinic proprietary nano-material technology to the marketplace. The technology and products are based on the idea that controlling blood vessel growth will improve human body management for a diverse set of medical applications ranging from wound healing to tissue reactivation.
OmegaGenesis is developing suitable nano-materials to manage human body functions at nano scale (the cell and sub-cell level) accelerating cellular-based biologic therapies where the growth of blood vessels determines the therapeutic outcome. These nano-materials will enable Physicians to treat disease at sub-cellular level in a non-destructive manner instead of treating the disease at the organ or tissue level.
Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with academic and corporate research partners as well as international partners to facilitate dual regulatory approval paths domestically and internationally.
It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.
OmegaGenesis is developing suitable nano-materials to manage human body functions at nano scale (the cell and sub-cell level) accelerating cellular-based biologic therapies where the growth of blood vessels determines the therapeutic outcome. These nano-materials will enable Physicians to treat disease at sub-cellular level in a non-destructive manner instead of treating the disease at the organ or tissue level.
Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with academic and corporate research partners as well as international partners to facilitate dual regulatory approval paths domestically and internationally.
It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.